As interest grows in better understanding the highly complex post-transcriptional environment in tumors, RNA-binding proteins have emerged as a class of potential cancer therapeutic targets. Recent research implicates them in MYC-driven cancers and in acute myeloid leukemia, to name just two examples, and the list is likely to lengthen.

You do not currently have access to this content.